Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. [artículo]
Por: Cortés-Funes Castro, Hernán [Oncología Médica]
| Hitt Sabag, Ricardo [Oncología Médica].
Colaborador(es): Servicio de Oncología Médica.
Editor: Annals of Oncology, 2012Descripción: 23(4):1016-22.Recursos en línea: Solicitar documento Resumen: The efficacy and safety of a novel combination of weekly paclitaxel and the epidermal growth factor receptor (EGFR) monoclonal antibody cetuximab for the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck were investigated.
| Tipo de ítem | Ubicación actual | Signatura | Estado | Fecha de vencimiento |
|---|---|---|---|---|
Artículo
|
PC5248 (Navegar estantería) | Disponible |
Formato Vancouver:
Hitt R, Irigoyen A, Cortés-Funes H, Grau JJ, García-Sáenz JA, Cruz-Hernández JJ, et al. Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of
patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. Ann Oncol. 2012 Apr;23(4):1016-22.
PMID: 21865152
Contiene 34 referencias
The efficacy and safety of a novel combination of weekly paclitaxel and the epidermal growth factor receptor (EGFR) monoclonal antibody cetuximab for the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck were investigated.
No hay comentarios para este ejemplar.